Ensuring Health Equity in the Delivery of Breakthrough Treatments for Trauma
in Honor of the Wedding of Jenn Gates and Nayel Nassar
The 501(c)(3) non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) is a global leader in psychedelic research. Since 1986, MAPS has been on a mission to create safe and legal opportunities to experience the benefits of psychedelics in medicine and society.
MAPS has completed the first of two phase 3 clinical trials utilizing MDMA-Assisted Therapy to treat PTSD. The results of this study can be found in this recent article published by the peer reviewed journal Nature Medicine.
Our goal is to ensure that those who currently have the least access to quality care are amongst the first to gain access to this new treatment modality once it becomes available. Through providing scholarships to trainings, we can focus on developing an MDMA therapist network that reflects the racial demographics of the countries where MDMA is a medicine, ensuring that patients receive competent care. Through subsidizing the cost of treatments, we can prioritize providing care to those who might not be able to afford it through our patient access program. Learn more about the Health Equity program.